Heather Francis

List of Publications by Year
in descending order

120 papers	4,513 citations	94381 37 h-index	123376 61 g-index
165 all docs	165 docs citations	165 times ranked	4055 citing authors

#	Article	IF	Citations
1	Mast cells in liver disease progression: An update on current studies and implications. Hepatology, 2022, 75, 213-218.	3.6	7
2	Melatonin receptor 1A, but not 1B, knockout decreases biliary damage and liver fibrosis during cholestatic liver injury. Hepatology, 2022, 75, 797-813.	3.6	9
3	Organoid Technology: Are Human Cholangiocyte Organoids Immune Protected?. Transplantation, 2022, 106, e249-e249.	0.5	1
4	FGF1 Signaling Modulates Biliary Injury and Liver Fibrosis in the Mdr2âˆ’/âˆ’ Mouse Model of Primary Sclerosing Cholangitis. Hepatology Communications, 2022, 6, 1574-1588.	2.0	2
5	Molecular Mechanisms Linking Risk Factors to Cholangiocarcinoma Development. Cancers, 2022, 14, 1442.	1.7	6
6	The Functional Roles of Immune Cells in Primary Liver Cancer. American Journal of Pathology, 2022, 192, 826-836.	1.9	17
7	Macrophage-Specific SCAP Promotes Liver and Adipose Tissue Damage in a Lean NAFLD Model: Lean, Mean, Proinflammatory Machine. Cellular and Molecular Gastroenterology and Hepatology, 2022, 14, 236-238.	2.3	1
8	Indole supplementation ameliorates MCD-induced NASH in mice. Journal of Nutritional Biochemistry, 2022, 107, 109041.	1.9	8
9	The protective effects of estrogen on biliary and liver damage are independent of ERâ€Î² signaling in female Mdr2 ^{â€/â€} mice. FASEB Journal, 2022, 36, .	0.2	0
10	Mast Cells Contribute to Hepatic Neurokinin1 Receptor Signaling, Subsequent Biliary Damage and Peribiliary Fibrosis Via TGFâ€Î²1 Signaling in MDR2â€/â€•Mouse Model of Primary Scelrosing Cholangitis. FASEB Journal, 2022, 36, .	0.2	0
11	The Effects of Taurocholic Acid on Biliary Damage and Liver Fibrosis Are Mediated by Calcitonin-Gene-Related Peptide Signaling. Cells, 2022, 11, 1591.	1.8	6
12	Conjugated Bile Acids activate Reactive Oxygen Speciesâ€p90RSKâ€Vascular Endothelial Growth Factor Receptor 3 signaling axis to promote lymphangiogenesis. FASEB Journal, 2022, 36, .	0.2	0
13	Development and Characterization of Human Primary Cholangiocarcinoma Cell Lines. American Journal of Pathology, 2022, 192, 1200-1217.	1.9	6
14	Mast cells selectively target large cholangiocytes during biliary injury via H2HRâ€•mediated cAMP/pERK1/2 signaling. Hepatology Communications, 2022, 6, 2715-2731.	2.0	6
15	Mast Cells Induce Ductular Reaction Mimicking Liver Injury in Mice Through Mast Cellâ€“Derived Transforming Growth Factor Beta 1 Signaling. Hepatology, 2021, 73, 2397-2410.	3.6	30
16	The interplay between mast cells, pineal gland, and circadian rhythm: Links between histamine, melatonin, and inflammatory mediators. Journal of Pineal Research, 2021, 70, e12699.	3.4	31
17	Cholangiocarcinoma: bridging the translational gap from preclinical to clinical development and implications for future therapy. Expert Opinion on Investigational Drugs, 2021, 30, 365-375.	1.9	10
18	Organoids and Spheroids as Models for Studying Cholestatic Liver Injury and Cholangiocarcinoma. Hepatology, 2021, 74, 491-502.	3.6	35

#	Article	IF	Citations
19	Doublecortinâ€Like Kinase Protein 1 in Cholangiocarcinoma: Is This the Biomarker and Target We Have Been Looking For?. Hepatology, 2021, 73, 4-6.	3.6	35
20	The Apelinâ€"Apelin Receptor Axis Triggers Cholangiocyte Proliferation and Liver Fibrosis During Mouse Models of Cholestasis. Hepatology, 2021, 73, 2411-2428.	3.6	24
21	Fructose Promotion of Intestinal and Liver Injury: A Sugar by Any Other Name That Isn't So Sweet. Hepatology, 2021, 73, 2092-2094.	3.6	4
22	Adipose tissue inflammation and systemic insulin resistance in mice with diet-induced obesity is possibly associated with disruption of PFKFB3 in hematopoietic cells. Laboratory Investigation, 2021, 101, 328-340.	1.7	14
23	Impact of Aging on Liver Cells and Liver Disease: Focus on the Biliary and Vascular Compartments. Hepatology Communications, 2021, 5, 1125-1137.	2.0	18
24	Mast Cells Promote Nonalcoholic Fatty Liver Disease Phenotypes and Microvesicular Steatosis in Mice Fed a Western Diet. Hepatology, 2021, 74, 164-182.	3.6	25
25	ASBT Vivoâ€Morpholino Decreases Hepatic Mast Cell, Fibrosis and Biliary Senescence in Mdr2 â€/â€•Mice. FASEB Journal, 2021, 35, .	0.2	0
26	Cyclic AMP Signaling in Biliary Proliferation: A Possible Target for Cholangiocarcinoma Treatment?. Cells, 2021, 10, 1692.	1.8	8
27	Inhibition of Secretin/Secretin Receptor Axis Ameliorates NAFLD Phenotypes. Hepatology, 2021, 74, 1845-1863.	3.6	16
28	Current Advances in Basic and Translational Research of Cholangiocarcinoma. Cancers, 2021, 13, 3307.	1.7	5
29	Heterogeneity of Hepatic Stellate Cells in Fibrogenesis of the Liver: Insights from Single-Cell Transcriptomic Analysis in Liver Injury. Cells, 2021, 10, 2129.	1.8	24
30	Feedback Signaling between Cholangiopathies, Ductular Reaction, and Non-Alcoholic Fatty Liver Disease. Cells, 2021, 10, 2072.	1.8	13
31	Adipocyte inducible 6-phosphofructo-2-kinase suppresses adipose tissue inflammation and promotes macrophage anti-inflammatory activation. Journal of Nutritional Biochemistry, 2021, 95, 108764.	1.9	3
32	Mast Cells Regulate Ductular Reaction and Intestinal Inflammation in Cholestasis Through Farnesoid X Receptor Signaling. Hepatology, 2021, 74, 2684-2698.	3.6	35
33	Methionine- and Choline-Deficient Dietâ€"Induced Nonalcoholic Steatohepatitis Is Associated with Increased Intestinal Inflammation. American Journal of Pathology, 2021, 191, 1743-1753.	1.9	15
34	Circadian Rhythm and Melatonin in Liver Carcinogenesis: Updates on Current Findings. Critical Reviews in Oncogenesis, 2021, 26, 69-85.	0.2	5
35	Biliary Epithelial Senescence in Liver Disease: There Will Be SASP. Frontiers in Molecular Biosciences, 2021, 8, 803098.	1.6	15
36	Modulation of the Tryptophan Hydroxylase 1/Monoamine Oxidaseâ€A/5â€Hydroxytryptamine/5â€Hydroxytryptamine Receptor 2A/2B/2C Axis Regulates Biliary Proliferation and Liver Fibrosis During Cholestasis. Hepatology, 2020, 71, 990-1008.	3.6	23

#	Article	IF	Citations
37	The emerging role of cellular senescence in renal diseases. Journal of Cellular and Molecular Medicine, 2020, 24, 2087-2097.	1.6	31
38	Knockout of the Tachykinin Receptor 1 in the Mdr2â^'/â^' (Abcb4â^'/â^') Mouse Model of Primary Sclerosing Cholangitis Reduces Biliary Damage and Liver Fibrosis. American Journal of Pathology, 2020, 190, 2251-2266.	1.9	9
39	Functional Role of the Secretin/Secretin Receptor Signaling During Cholestatic Liver Injury. Hepatology, 2020, 72, 2219-2227.	3.6	18
40	Kupffer Cells. American Journal of Pathology, 2020, 190, 2185-2193.	1.9	80
41	Hepatocyte Autophagy: Maintaining a Toxicâ€Free Environment. Hepatology, 2020, 72, 371-374.	3.6	3
42	Concise Review: Functional Roles and Therapeutic Potentials of Long Non-coding RNAs in Cholangiopathies. Frontiers in Medicine, 2020, 7, 48.	1.2	8
43	Amelioration of Large Bile Duct Damage by Histamine-2 Receptor Vivo-Morpholino Treatment. American Journal of Pathology, 2020, 190, 1018-1029.	1.9	13
44	Neuroendocrine Changes in Cholangiocarcinoma Growth. Cells, 2020, 9, 436.	1.8	7
45	Biliary damage and liver fibrosis are ameliorated in a novel mouse model lacking l-histidine decarboxylase/histamine signaling. Laboratory Investigation, 2020, 100, 837-848.	1.7	18
46	Melatonin and circadian rhythms in liver diseases: Functional roles and potential therapies. Journal of Pineal Research, 2020, 68, e12639.	3.4	63
47	Bile Acid Receptor Therapeutics Effects on Chronic Liver Diseases. Frontiers in Medicine, 2020, 7, 15.	1.2	23
48	Cholangiocarcinoma: novel therapeutic targets. Expert Opinion on Therapeutic Targets, 2020, 24, 345-357.	1.5	25
49	Indole Alleviates Dietâ€Induced Hepatic Steatosis and Inflammation in a Manner Involving Myeloid Cell 6â€Phosphofructoâ€2â€Kinase/Fructoseâ€2,6â€Biphosphatase 3. Hepatology, 2020, 72, 1191-1203.	3.6	67
50	Downregulation of p16 Decreases Biliary Damage and Liver Fibrosis in the Mdr2[/] Mouse Model of Primary Sclerosing Cholangitis. Gene Expression, 2020, 20, 89-103.	0.5	20
51	The Dynamic Interplay Between Mast Cells, Aging/Cellular Senescence, and Liver Disease. Gene Expression, 2020, 20, 77-88.	0.5	16
52	Mast Cell Signaling Regulates Biliary Farnesoid X Receptor and Apical Sodium Bile Acid Transporter Expression During Cholestatic Liver Injury. FASEB Journal, 2020, 34, 1-1.	0.2	0
53	FGF1 receptor antagonist decreases biliary proliferation, fibrosis, and senescence in a mouse model of chronic cholestasis. FASEB Journal, 2020, 34, 1-1.	0.2	0
54	Ductular Reaction in Liver Diseases: Pathological Mechanisms and Translational Significances. Hepatology, 2019, 69, 420-430.	3.6	251

#	Article	IF	Citations
55	Secretin/secretin receptor signaling mediates biliary damage and liver fibrosis in earlyâ€stage primary biliary cholangitis. FASEB Journal, 2019, 33, 10269-10279.	0.2	32
56	Downregulation of hepatic stem cell factor by Vivo-Morpholino treatment inhibits mast cell migration and decreases biliary damage/senescence and liver fibrosis in Mdr2â^'/â^' mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 165557.	1.8	25
57	Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the Mdr2â^'/â^' mouse model of primary sclerosing cholangitis (PSC). EBioMedicine, 2019, 48, 130-142.	2.7	29
58	Possible application of melatonin treatment in human diseases of the biliary tract. American Journal of Physiology - Renal Physiology, 2019, 317, G651-G660.	1.6	11
59	Knockout of Î±-calcitonin gene-related peptide attenuates cholestatic liver injury by differentially regulating cellular senescence of hepatic stellate cells and cholangiocytes. Laboratory Investigation, 2019, 99, 764-776.	1.7	14
60	Intercellular Communication between Hepatic Cells in Liver Diseases. International Journal of Molecular Sciences, 2019, 20, 2180.	1.8	48
61	Dual Role of Bile Acids on the Biliary Epithelium: Friend or Foe?. International Journal of Molecular Sciences, 2019, 20, 1869.	1.8	21
62	Preclinical insights into cholangiopathies: disease modeling and emerging therapeutic targets. Expert Opinion on Therapeutic Targets, 2019, 23, 461-472.	1.5	18
63	Pinealectomy or light exposure exacerbates biliary damage and liver fibrosis in cholestatic rats through decreased melatonin synthesis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 1525-1539.	1.8	18
64	Amelioration of Ductular Reaction by Stem Cell Derived Extracellular Vesicles in MDR2 Knockout Mice via Lethalâ€7 microRNA. Hepatology, 2019, 69, 2562-2578.	3.6	32
65	Prolonged intake of desloratadine: mesenteric lymphatic vessel dysfunction and development of obesity/metabolic syndrome. American Journal of Physiology - Renal Physiology, 2019, 316, G217-G227.	1.6	18
66	Knockout of l-Histidine Decarboxylase Prevents Cholangiocyte Damage and Hepatic Fibrosis in Mice Subjected to High-Fat Diet Feeding via Disrupted Histamine/Leptin Signaling. American Journal of Pathology, 2018, 188, 600-615.	1.9	30
67	Disruption of adenosine 2A receptor exacerbates NAFLD through increasing inflammatory responses and SREBP1c activity. Hepatology, 2018, 68, 48-61.	3.6	57
68	Blocking H1/H2 histamine receptors inhibits damage/fibrosis in Mdr2â€"/â€" mice and human cholangiocarcinoma tumorigenesis. Hepatology, 2018, 68, 1042-1056.	3.6	50
69	Expression of STING Is Increased in Liver Tissues From Patients With NAFLD and Promotes Macrophage-Mediated Hepatic Inflammation and Fibrosis in Mice. Gastroenterology, 2018, 155, 1971-1984.e4.	0.6	234
70	The Secretin/Secretin Receptor Axis Modulates Ductular Reaction and Liver Fibrosis through Changes in Transforming Growth Factor-Î²1â€"Mediated Biliary Senescence. American Journal of Pathology, 2018, 188, 2264-2280.	1.9	31
71	Knockout of secretin receptor reduces biliary damage and liver fibrosis in Mdr2â^'/â^' mice by diminishing senescence of cholangiocytes. Laboratory Investigation, 2018, 98, 1449-1464.	1.7	41
72	Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2â^'/â^' mice and human primary sclerosing cholangitis. Laboratory Investigation, 2018, 98, 1465-1477.	1.7	29

#	Article	IF	Citations
73	Bile duct ligationâ€“induced biliary hyperplasia, hepatic injury, and fibrosis are reduced in mast cellâ€“deficient KitWâ€‹sh mice. Hepatology, 2017, 65, 1991-2004.	3.6	51
74	Substance P increases liver fibrosis by differential changes in senescence of cholangiocytes and hepatic stellate cells. Hepatology, 2017, 66, 528-541.	3.6	67
75	Knockdown of Hepatic Gonadotropin-Releasing Hormone by Vivo-Morpholino Decreases Liver Fibrosis in Multidrug Resistance Gene 2 Knockout Mice by Down-Regulation of miR-200b. American Journal of Pathology, 2017, 187, 1551-1565.	1.9	14
76	The emerging role of mast cells in liver disease. American Journal of Physiology - Renal Physiology, 2017, 313, G89-G101.	1.6	34
77	Prolonged darkness reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miRâ€200b downâ€regulation. FASEB Journal, 2017, 31, 4305-4324.	0.2	45
78	Regulation of Cellular Senescence by miR-34a in Alcoholic Liver Injury. American Journal of Pathology, 2017, 187, 2788-2798.	1.9	60
79	Forkhead box A2 regulates biliary heterogeneity and senescence during cholestatic liver injury in miceâ€¡. Hepatology, 2017, 65, 544-559.	3.6	43
80	Isolation and characterization of hepatic mast cells from cholestatic rats. Laboratory Investigation, 2016, 96, 1198-1210.	1.7	22
81	Pathogenesis of Kupffer Cells in Cholestatic Liver Injury. American Journal of Pathology, 2016, 186, 2238-2247.	1.9	74
82	Inhibition of mast cellâ€secreted histamine decreases biliary proliferation and fibrosis in primary sclerosing cholangitis Mdr2â’/â’ mice. Hepatology, 2016, 64, 1202-1216.	3.6	63
83	Inhibition of Mast Cell-Derived Histamine Decreases Human Cholangiocarcinoma Growth and Differentiation via c-Kit/Stem Cell Factorâ€“Dependent Signaling. American Journal of Pathology, 2016, 186, 123-133.	1.9	61
84	Ischemia reperfusion of the hepatic artery induces the functional damage of large bile ducts by changes in the expression of angiogenic factors. American Journal of Physiology - Renal Physiology, 2015, 309, G865-G873.	1.6	6
85	Histamine restores biliary mass following carbon tetrachloride-induced damage in a cholestatic rat model. Digestive and Liver Disease, 2015, 47, 211-217.	0.4	7
86	Development and functional characterization of extrahepatic cholangiocyte lines from normal rats. Digestive and Liver Disease, 2015, 47, 964-972.	0.4	10
87	Gonadotropin-Releasing Hormone Stimulates Biliary Proliferation by Paracrine/Autocrine Mechanisms. American Journal of Pathology, 2015, 185, 1061-1072.	1.9	18
88	Bile acid signaling and biliary functions. Acta Pharmaceutica Sinica B, 2015, 5, 123-128.	5.7	70
89	Functional Role of MicroRNAâ€200 Family in Human Gall Bladder Cancer Stem Cells. FASEB Journal, 2015, 29, 45.7.	0.2	0
90	Knockout of histidine decarboxylase decreases bile duct ligation-induced biliary hyperplasia via downregulation of the histidine decarboxylase/VEGF axis through PKA-ERK1/2 signaling. American Journal of Physiology - Renal Physiology, 2014, 307, G813-G823.	1.6	20

#	Article	IF	Citations
91	Prolonged exposure of cholestatic rats to complete dark inhibits biliary hyperplasia and liver fibrosis. American Journal of Physiology - Renal Physiology, 2014, 307, G894-G904.	1.6	31
92	Secretin Stimulates Biliary Cell Proliferation by Regulating Expression of MicroRNA 125b and MicroRNA let7a in Mice. Gastroenterology, 2014, 146, 1795-1808.e12.	0.6	83
93	Molecular mechanisms of stem cell therapy in alcoholic liver disease. Digestive and Liver Disease, 2014, 46, 391-397.	0.4	20
94	Vitamin D and GI cancers: shedding some light on dark diseases. Annals of Translational Medicine, 2014, 2, 9.	0.7	20
95	Recent advances in the morphological and functional heterogeneity of the biliary epithelium. Experimental Biology and Medicine, 2013, 238, 549-565.	1.1	64
96	Inhibition of histidine decarboxylase ablates the autocrine tumorigenic effects of histamine in human cholangiocarcinoma. Gut, 2012, 61, 753-764.	6.1	69
97	Histamine regulation of biliary proliferation. Journal of Hepatology, 2012, 56, 1204-1206.	1.8	19
98	Reply: H3 or H4 histamine receptors: That which contributes to suppressing human cholangiocarcinoma progression still remains to be clarified. Hepatology, 2012, 56, 1183-1183.	3.6	0
99	Role of stem cell factor and granulocyte colony-stimulating factor in remodeling during liver regeneration. Hepatology, 2012, 55, 209-221.	3.6	55
100	Histamine and histamine receptor regulation of gastrointestinal cancers. Translational Gastrointestinal Cancer, 2012, 1, 215-227.	3.0	27
101	The H4 histamine receptor agonist, clobenpropit, suppresses human cholangiocarcinoma progression by disruption of epithelial mesenchymal transition and tumor metastasis. Hepatology, 2011, 54, 1718-1728.	3.6	66
102	Melatonin inhibits cholangiocyte hyperplasia in cholestatic rats by interaction with MT1 but not MT2 melatonin receptors. American Journal of Physiology - Renal Physiology, 2011, 301, G634-G643.	1.6	53
103	Emerging Role of Chronic Cannabis Usage and Hyperemesis Syndrome. Southern Medical Journal, 2011, 104, 665.	0.3	4
104	Knockout of secretin receptor reduces large cholangiocyte hyperplasia in mice with extrahepatic cholestasis induced by bile duct ligation. Hepatology, 2010, 52, 204-214.	3.6	79
105	Taurocholic acid prevents biliary damage induced by hepatic artery ligation in cholestatic rats. Digestive and Liver Disease, 2010, 42, 709-717.	0.4	15
106	Histamine regulation of hyperplastic and neoplastic cell growth in cholangiocytes. World Journal of Gastrointestinal Pathophysiology, 2010, 1, 38.	0.5	8
107	Histamine and specific histamine receptors increase normal cholangiocyte growth via differential mechanisms. FASEB Journal, 2010, 24, 1000.3.	0.2	0
108	H3 Histamine Receptorâ€"Mediated Activation of Protein Kinase CÎ± Inhibits the Growth of Cholangiocarcinoma <i>In vitro</i> and <i>In vivo</i>. Molecular Cancer Research, 2009, 7, 1704-1713.	1.5	60

#	Article	IF	Citations
109	Small mouse cholangiocytes proliferate in response to H1 histamine receptor stimulation by activation of the IP₃/CaMK I/CREB pathway. American Journal of Physiology - Cell Physiology, 2008, 295, C499-C513.	2.1	125
110	Proliferating Cholangiocytes: A Neuroendocrine Compartment in the Diseased Liver. Gastroenterology, 2007, 132, 415-431.	0.6	264
111	H3 histamine receptor agonist inhibits biliary growth of BDL rats by downregulation of the cAMP-dependent PKA/ERK1/2/ELK-1 pathway. Laboratory Investigation, 2007, 87, 473-487.	1.7	77
112	Ca2+-Dependent Cytoprotective Effects of Ursodeoxycholic and Tauroursodeoxycholic Acid on the Biliary Epithelium in a Rat Model of Cholestasis and Loss of Bile Ducts. American Journal of Pathology, 2006, 168, 398-409.	1.9	68
113	Vascular Endothelial Growth Factor Stimulates Rat Cholangiocyte Proliferation Via an Autocrine Mechanism. Gastroenterology, 2006, 130, 1270-1282.	0.6	188
114	Bile acid interactions with cholangiocytes. World Journal of Gastroenterology, 2006, 12, 3553.	1.4	147
115	Administration of r-VEGF-A prevents hepatic artery ligation-induced bile duct damage in bile duct ligated rats. American Journal of Physiology - Renal Physiology, 2006, 291, G307-G317.	1.6	67
116	cAMP stimulates the secretory and proliferative capacity of the rat intrahepatic biliary epithelium through changes in the PKA/Src/MEK/ERK1/2 pathway. Journal of Hepatology, 2004, 41, 528-537.	1.8	110
117	Taurocholate prevents the loss of intrahepatic bile ducts due to vagotomy in bile duct-ligated rats. American Journal of Physiology - Renal Physiology, 2003, 284, G837-G852.	1.6	46
118	Taurocholate feeding prevents CCl₄-induced damage of large cholangiocytes through PI3-kinase-dependent mechanism. American Journal of Physiology - Renal Physiology, 2003, 284, G290-G301.	1.6	35
119	Bile acid depletion and repletion regulate cholangiocyte growth and secretion by a phosphatidylinositol 3-kinaseâ€“dependent pathway in rats. Gastroenterology, 2002, 123, 1226-1237.	0.6	74
120	Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha. Hepatology, 2002, 35, 1041-1052.	3.6	122